|| Checking for direct PDF access through Ovid
A STUDY OF CCNU, used as a single agent or in combination with other agents, was performed in selected tumor types. CCNU was administered by mouth every 6 weeks as a single agent (130 mg/m2 or in combination (90 mg/m2) with other marrow toxic drugs. Nausea and vomiting were the most common side effects. Thrombocytopenia and leukopenia were also commonly seen appearing as delayed, often prolonged, side effects. Sixty-eight patients were treated in this series. Favorable responses were observed in four of four patients with Hodgkin's disease (combined with vinblastine and prednisone), seven of 12 non-Hodgkin's lymphoma (combined with vincristine and prednisone), three of 13 patients with malignant melanoma, one of three with carcinoma of the stomach, and one of 15 with carcinoma of the lung.